Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03418-4, published online 3 January 2025.
In the version of the article initially published, the y-axis label in Fig. 3f was incorrect and has now been amended to “% Cas3+ of live target cells”. Additionally, this article was originally published under Creative Commons Attribution 4.0 International license, CC-BY-NC-ND, © The Author(s). It is now available under a Creative Commons Attribution 4.0 International license, CC-BY, © The Author(s). These corrections have been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Borgers, J.S.W., Lenkala, D., Kohler, V. et al. Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med 31, 3206 (2025). https://doi.org/10.1038/s41591-025-03896-0
Published:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03896-0
